AYOXXA Biosystems GmbH

AYOXXA Biosystems GmbH is a German company focused on developing innovative diagnostic solutions that enhance biomarker analysis, facilitating advancements in personalized medicine and clinical diagnostics. AYOXXA Biosystems GmbH, founded in 2010 in Cologne, Germany, specializes in advanced diagnostic platforms. With a total of 4 deals, the most recent funding round was a Series B, securing EUR 2. 30 mn from BioMed Partners and Grazia Equity on March 14, 2022.

The company has raised a total of EUR 2. 30 mn and has a current valuation of EUR 22. 48 mn. AYOXXA specializes in the development and provision of innovative diagnostic solutions aimed at enhancing biomarker analysis and diagnostic processes.

Their core product offerings include a proprietary multiplex protein detection platform designed for high-throughput analysis of biomarkers in various biological samples. This technology supports critical applications in personalized medicine, drug development, and clinical diagnostics, providing rapid and accurate health insights for healthcare professionals and researchers. Their products are marketed globally, with a focus on Europe and North America, catering to a wide array of clients, including academic institutions, pharmaceutical companies, and clinical laboratories. AYOXXA's revenue primarily comes from sales of its diagnostic platforms and associated consumables, which are essential for biomarker analysis.

The company engages in B2B transactions where clients purchase necessary equipment and reagents. Partnerships with research institutions and healthcare organizations integrate AYOXXA's technology into diagnostic workflows, with pricing plans tailored to client needs. The flagship products generate significant revenue and foster ongoing relationships through regular supply contracts. In March 2022, AYOXXA raised EUR 2.

30 mn to drive the global commercialization of its LUNARIS(TM) platform. The company plans to expand its product lineup and is targeting growth in new markets beyond Europe and North America, although specific regions or timelines have yet to be disclosed.